



Advanced Regenerative
Manufacturing Institute,
Inc.
400 Commercial Street
Manchester, NH 03101
www.armiusa.org

REQUEST FOR QUOTES (RFQ)
– ARMI & ARPA-H REACT –
IDENTIFICATION OF CRITICAL QUALITY ATTRIBUTES OF SC-ISLETS

RFQ Issue Date: July 30, 2026 (reposted with modifications on August 5, 2026)

RFQ Closing Date: Quotes shall be submitted to and received by Dr. Thomas Bollenbach at tbollenbach@armiusa.org **no later than 5:00PM (EST), August 12, 2026**. The Laboratory is responsible for verifying a timely and complete submission.

RFQ Title: ARMI & ARPA-H REACT – SC-ISLET DIFFERENTIATION AND *IN VITRO* TESTING FOR COLLABORATIVE IDENTIFICATION OF CRITICAL QUALITY ATTRIBUTES AND CRITICAL PROCESS PARAMETERS

Issuing Entity: Advanced Regenerative Manufacturing Institute, Inc. (“ARMI”) under the Advanced Research Projects Agency – Health (“ARPA-H”) Resilient Systems Office (“RSO”) Resilient Extended Automatic Cell Therapies (“REACT”) program, contract number 75N99226C00001.

Overview: ARMI is seeking qualified laboratories with unique human SC-islet differentiation protocols in a study to identify the Critical Quality Attributes (“CQAs”) of SC-islets necessary for preclinical assessment and scale up for manufacturing.

Point of Contact: Dr. Thomas Bollenbach, tbollenbach@armiusa.org

RFQ Attachments:

Attachment 1: Scope of Work/Objectives

Attachment 2: Quote Requirements

Attachment 3: Provisions and Clauses

Attachment 4: Federal Compliance – FAR provisions

ATTACHMENT 1 – SCOPE OF WORK/OBJECTIVES –

Objectives:

1. The selected laboratories will generate SC-islets according to their unique differentiation protocol.
 - a. Samples of cells and cell culture media from each stage of differentiation and the resulting SC-islet clusters will be sent to ARMI for deep characterization.
2. Upon completion of the differentiation, the selected laboratories will implant, or collaborate with a partner laboratory to implant, SC-islets into a streptozotocin-, diphtheria toxin- or other induced immunodeficient mouse model of diabetes.
3. The study will require approximately 8 sham mice and 8 mice per treatment group.
4. Final alignment on the *in vivo* study design and analyses to be conducted by all labs may be determined by consensus after convening selected participants. The following analyses are an example of what may be conducted during in-life phase.
 - a. Time to reversal of insulin-dependence
 - b. Fasted and stimulated human C-peptide release at defined time points
 - c. Percentage efficacy
 - d. *In vitro* glucose uptake AUC
 - e. Human C-peptide accumulation
 - f. Global serum analysis
 - g. Serum human pro-insulin versus mature insulin ratio

Approximate Timelines:

1. Laboratories specify approximate differentiation protocol duration.
2. In-life phase of project may last up to 24 weeks post-induction pending input from selected participants.
3. Laboratories must submit an interim report by December 18, 2026.
4. A final report must be submitted within 45 days of the end of the in-life study.

Desired Outcome:

ARMi will apply advanced computational techniques to understand correlations between *in vitro*, high dimensional, deep characterization data and laboratory provided *in vivo* data to identify SC-islet quality control specifications.

ATTACHMENT 2 – QUOTE REQUIREMENTS–

Subcontracts will be issued as a time and material agreement and should be quoted accordingly.

Quote Requirements:

1. Detailed budget breakdown, including line items for labor, materials, direct and indirect costs.
2. Details whether the laboratory tested islets *in vivo* before.
3. The number of stages of differentiation in the protocol.
4. What scale the laboratory normally performs the differentiation at.
5. What cell line(s) the laboratory uses for generating islets.
6. List of resources and materials that will be provided by the laboratory (i.e. not included within the quoted materials and costs).
7. Estimated duration of differentiation protocol.
8. Identification of the number of *in vivo* treatment groups to be analyzed.
9. If applicable, citations for any relevant, published patents or publications associated with the laboratories' proposed SC-islet differentiation protocol.
10. If applicable, disclosure of any potential conflicts of interest for ARMI internal evaluation.

ATTACHMENT 3

– PROVISIONS AND CLAUSES –

Legal Structure and Authority

Each quote shall include the legal name of the organization and description of the entity type (a sole proprietorship, a partnership, a corporation). Each quote shall be signed by a person legally authorized to bind the selected Contractor to a contract.

The selected contractor will be responsible for the execution of all deliverables as outlined within this scope of work.

Data Rights

Given the nature of this project, ARMI will require a full-paid license to use all *in vivo* data collected by the laboratory for data analysis and ultimately identification of the SC-islet CQAs.

Conflict of Interest

The organization submitting a quote in response to this RFQ must disclose any direct or indirect conflict of interest, regardless of whether it is actual or perceived.

Compliance with Law

The selected Contractor shall comply with all applicable provisions of federal, state and local law both in its response hereto and in provision of any services by the selected Contractor.

Reservation of Rights

ARMi reserves the right to accept any quote, in whole or in part, to negotiate further regarding any terms of the proposal to achieve the best proposal as determined by ARMI at its sole discretion and to reject any or all quotes for any reason whatsoever, should it be deemed in the best interests of ARMI to do so.

ARMi reserves the right to waive or disregard any informality, irregularity or deficiency in any proposal received.

Work Authorization

The selected Contractor shall not commence any work without being given a written Notice to Proceed.



Advanced Regenerative
Manufacturing Institute,
Inc.
400 Commercial Street
Manchester, NH 03101
www.armiusa.org

Termination

ARMI reserves the right to terminate the contract upon five (5) days written notice should the selected Contractor fail substantially to perform in accordance with the Agreement. In addition,

ARMI reserves the right to terminate the contract at any time or to reduce the Scope of Services in order to be consistent with the availability of funds.

ATTACHMENT 4

–FEDERAL COMPLIANCE–

The selected laboratory must comply with the following provisions as applicable:

RFO FAR Clause:

52.203-3 Gratuities (APR 1984)

52.203-6 Restrictions on Subcontractor Sales to the Government (JUN2020) (Alternate I)
(JUN 2021)

52.203-13 Contractor Code of Business Ethics and Conduct (NOV 2021)

52.203-17 Contractor Employee Whistleblower Rights (NOV 2023)

52.203-19 Prohibition on Requiring Certain Internal Confidentiality Agreements or
Statements (JAN 2017)

52.204-9 Personal Identity Verification of Contractor Personnel (JAN 2011)

52.204-13 System for Award Management—Maintenance (DEVIATION DATE)

52.209-6 Protecting the Government's Interest When Subcontracting with Contractors
Debarred, Suspended, or Proposed for Debarment (DEVIATION DATE)

52.209-9 Updates of Publicly Available Information Regarding Responsibility Matters
(DEVIATION DATE)

52.209-10 Prohibition on Contracting with Inverted Domestic Corporations (DEVIATION
DATE)

52.219-8 Utilization of Small Business Concerns (DEVIATION DATE)

52.219-9, ALT II Small Business Subcontracting Plan, with Alternate II (DEVIATION DATE)

52.219-14 Limitations on Subcontracting (DEVIATION DATE)

52.219-16 Liquidated Damages—Subcontracting Plan (DEVIATION DATE)

52.222-3 Convict Labor (DEVIATION DATE)

52.222-35 Equal Opportunity for Veterans (DEVIATION DATE)

52.222-36 Equal Opportunity for Workers with Disabilities (DEVIATION DATE)

52.222-37 Employment Reports on Veterans (DEVIATION DATE)

52.222-40 Notification of Employee Rights Under the National Labor Relations Act
(DEVIATION DATE)

52.222-41 Service Contract Labor Standards (DEVIATION DATE)

52.222-42 Statement of Equivalent Rates for Federal Hires (MAY 2014)

52.222-43 Fair Labor Standards Act and Service Contract Labor Standards-Price (Multiple Year and Option Contracts) (DEVIATION DATE)

52.222-50 Combating Trafficking in Persons (DEVIATION DATE)

52.222-54 Employment Eligibility Verification (DEVIATION DATE)

52.222-62 Paid Sick Leave Under Executive Order 13706 (DEVIATION DATE)

52.222-90 Addressing DEI Discrimination by Federal Contractors (DEVIATION DATE)

52.223-23 Sustainable Products and Services (DEVIATION DATE)

52.224-3 Privacy Training (JAN 2017)

52.226-8 Encouraging Contractor Policies to Ban Text Messaging While Driving (MAY 2024)

52.227-17 Rights in Data-Special Works (Dec 2007)

52.229-12 Tax on Certain Foreign Procurements (DEVIATION DATE)

52.232-33 Payment by Electronic Funds Transfer—System for Award Management (OCT 2018)

52.232-40 Providing Accelerated Payments to Small Business Subcontractors (MAR 2023)

52.233-3 Protest After Award (DEVIATION DATE)

52.233-4 Applicable Law for Breach of Contract Claim (DEVIATION DATE)

52.240-91 Security Prohibitions and Exclusions (DEVIATION DATE)

52.240-93 Basic Safeguarding of Covered Contractor Information Systems (DEVIATION DATE)

52.244-6 Subcontracts for Commercial Products and Commercial (DEVIATION DATE)

HHSAR:

352.203-70 Anti-lobbying (DEC 2015)

352.219-71 Mentor-Protégé Program Reporting Requirements (DEC 2015)

352.232-71 Electronic Submission of Payment Requests (FEB 2022)

352.239-74 Electronic and Information Technology Accessibility (DEC 2015)